与克拉 (Mitragyna speciosa) 相关的肝损伤:一个系统性审查
Journal of addiction medicine
|March 10, 2026
概括
Kratom (Mitragyna speciosa) 的使用与肝损伤有关,通常以黄和肝酶升高的形式呈现. 虽然大多数病例在停止使用kratom后得到改善,但有些人需要进行肝移植,这凸显了进一步研究的必要性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉 (Mitragyna speciosa) 是一种精神活性草药产品,在疼痛,焦虑和阿片类药物戒断管理方面越来越受欢迎.
- 尽管它作为天然食补充剂进行营销,但人们对副作用,包括严重的肝毒性产生了担忧.
研究的目的:
- 系统地审查有关 kratom 使用及其与肝损伤相关的现有文献.
- 为了整合病例报告,并确定克拉诱导的肝毒性模式.
主要方法:
- 按照PRISMA 2020指南进行了系统审查.
- 所有发表的关于使用kratom和肝脏毒性的研究都被纳入了分析.
主要成果:
- 31项研究确定了32例与克拉相关的肝损伤病例,主要是成年男性,经常使用多种物质.
- 肝损伤通常伴有黄和肝酶升高,主要以胆固醇性模式呈现.
- 虽然大多数患者在停止使用kratom后得到改善,但有4例病例进展到肝移植,这表明潜在的严重后果.
结论:
- Kratom 使用暂时与肝损伤有关,在许多报告的病例中,这种模式表明有因果关系.
- 关于 kratom 剂量,形式和持续时间的不一致报告妨碍了损伤的完整描述.
- 进一步的研究至关重要,以阐明加诱导的肝损伤的机制,并指导临床和公共卫生战略.
更多相关视频
11:14Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
Published on: October 2, 2016
12.2K
09:44Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
11.2K
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
246
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
01:24Drug Toxicity: Risk factors
88
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
88
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
01:00Drug Toxicity: Overview
114
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
114
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307